Die weltweit einzige bekannte Prüftherapie in der klinischen Phase 3 zur Behandlung von SBMA AJ201 (Rosolutamid) ist ein in der Erprobung befindliches, oral verabreichtes niedermolekulares Präparat, das darauf abzielt, mehrere Krankheitsmechanismen der spinalen und bulbären Muskelatrophie...
Hence then, the article about annji pharmaceutical uberfuhrt aj201 in die zulassungsrelevante phase 3 studie roma kd zur behandlung der spinalen und bulbaren muskelatrophie sbma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA) )
Also on site :
- ‘The Voice’s Kayleigh Matthews Stuns Coaches With Four-Chair Turn on Vince Gill Cover
- Kylie Jenner Bachelorette Weekend Thriller Getting Hulu Series Order From Kim Kardashian, Lauren Oliver & Kapital Entertainment
- ‘Riverdance’ & ‘Lord of the Dance’ Fans Shocked as Michael Flatley Shares His Wife’s Death at 52: What Happened?